Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...
Capricor Therapeutics (CAPR) stock gains as company plans to seek FDA approval for its lead candidate deramiocel (CAP-1002) ...
Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
18h
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...
Year-to-date, Capricor Therapeutics has outperformed the broader market, boasting a YTD increase of 62.78%, compared to the S&P 500’s modest 19.88% rise. This performance underscores Capricor’s strong ...
Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Capricor will receive an upfront payment of $20 million subject to execution of the definitive agreement, and there are potential additional development and sales-based milestone payments to Capricor ...
Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese ...
Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...
On Tuesday, major U.S. indices closed higher, with the Dow Jones Industrial Average gaining 0.2% to reach 42,208.22.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback